Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2012

01-10-2012 | Bone and Soft Tissue Sarcomas

Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study

Authors: C. Colombo, MD, U. Ronellenfitsch, MD, Z. Yuxin, MD, P. Rutkowski, MD, R. Miceli, PhD, E. Bylina, MD, P. Hohenberger, MD, PhD, C. P. Raut, MD, A. Gronchi, MD

Published in: Annals of Surgical Oncology | Issue 11/2012

Login to get access

Abstract

Background

The duodenum is a rare site of primary gastrointestinal stromal tumor (GIST). Overall (OS) and disease-free survival (DFS) after limited resection (LR) versus pancreaticoduodenectomy (PD) were studied.

Methods

All patients who underwent surgery for primary, localized duodenal GIST between 2000 and 2011 were identified from four prospective institutional databases. OS and DFS were calculated by Kaplan–Meier method. Univariate analysis was performed.

Results

Eighty-four patients (median follow-up 42 months) underwent LR (n = 56, 67 %) or PD (n = 28, 33 %). Patients in the PD group had a larger median tumor size (7 cm vs. 5 cm, p = 0.024) and higher mitotic count (39 % vs. 19 % >5/50 high-power fields, p = 0.05). Complications were observed in five patients (9 %) in the LR group and ten patients (36 %) in the PD group. OS and DFS for the entire cohort were 89 % and 64 % at 5 years, respectively. No difference in outcome between LR and PD were observed. Eleven patients were treated with preoperative IM. A major RECIST response was obtained in nine (80 %), whereas two had stable disease. Twenty-three patients received postoperative Imatinib (IM). A trend toward a better OS in IM-treated patients could be detected only in the high-risk group.

Conclusions

Type of duodenal resection does not impact outcome. The choice should be determined by duodenal site of origin and tumor size. IM may be considered in cases at high risk of recurrence; in neoadjuvant setting, IM might facilitate resection and possibly increase the chance of preserving normal biliary and pancreatic anatomy.
Literature
1.
Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655–64.PubMedCrossRef
2.
Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.PubMedCrossRef
3.
4.
Buchs NC, Bucher P, Gervaz P, Ostermann S, Pugin F, Morel P. Segmental duodenectomy for gastrointestinal stromal tumor of the duodenum. World J Gastroenterol. 2010;16:2788–92.PubMedCrossRef
5.
Casali PG, Lost L, Reichardt, Schlemmer M, Blay JY. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:64–7.PubMed
6.
Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). EJSO. 2009;35:739–45.PubMedCrossRef
7.
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.PubMedCrossRef
8.
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.PubMedCrossRef
9.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.PubMedCrossRef
10.
Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27–38.CrossRef
11.
Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;7:114–9.CrossRef
12.
Heinze G, Ploner M. SAS and SPLUS programs to perform Cox regression without convergence problems. Comput Methods Programs Biomed. 2002;67:217–23.PubMedCrossRef
13.
Beham A, Schaefer IM, Cameron S, von Hammerstein K, Füzesi L, Ramadori G, Ghadimi MB. Duodenal GIST: a single-center experience. Int J Colorectal Dis. 2012. doi:10.​1007/​s00384-012-1432-8.
14.
Chung JC, Chu CW, Cho GS, Shin EJ, Lim CW, Kim HC, Song PO. Management and outcome of gastrointestinal stromal tumors of the duodenum. J Gastrointest Surg. 2010;14:880–3.PubMedCrossRef
15.
Tien YW, Lee CY, Huang CC, Hu RH, Lee PH. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol. 2010;17:109–14.PubMedCrossRef
16.
Gronchi A, Raut CP. The combination of Surgery and Imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol. 2012;19:1051–5.PubMedCrossRef
17.
Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.PubMedCrossRef
18.
Blanke C, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.PubMedCrossRef
19.
Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764–74.PubMedCrossRef
20.
Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–7.PubMedCrossRef
21.
Corless CL, Ballman BV, Antonescu C, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28(Suppl):10006.
22.
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247–53.CrossRef
23.
Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093–103.PubMedCrossRef
24.
Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011. doi:10.​1007/​s12032-011-0074-y.
Metadata
Title
Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study
Authors
C. Colombo, MD
U. Ronellenfitsch, MD
Z. Yuxin, MD
P. Rutkowski, MD
R. Miceli, PhD
E. Bylina, MD
P. Hohenberger, MD, PhD
C. P. Raut, MD
A. Gronchi, MD
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2559-0

Other articles of this Issue 11/2012

Annals of Surgical Oncology 11/2012 Go to the issue

Thoracic Oncology

CCR7 and VEGF-C: Molecular Indicator of Lymphatic Metastatic Recurrence in pN0 Esophageal Squamous Cell Carcinoma after Ivor-Lewis Esophagectomy?

Colorectal Cancer

Clinical Outcomes of Patients with Microsatellite-Unstable Colorectal Carcinomas Depend on L1 Methylation Level

Hepatobiliary Tumors

The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection

Gynecologic Oncology

Systematic Pelvic and Aortic Lymphadenectomy in Advanced Ovarian Cancer Patients at the Time of Interval Debulking Surgery: A Double-Institution Case–Control Study

Pancreatic Tumors

Complications and Toxicity After Abdominal and Pelvic Hypoxic Stop-Flow Perfusion Chemotherapy: Incidence and Assessment of Risk Factors

Endocrine Tumors

Significance of Size of Lymph Node Metastasis on Postsurgical Stimulated Thyroglobulin Levels After Prophylactic Unilateral Central Neck Dissection in Papillary Thyroid Carcinoma